| drug | Paromomycin |
| classification | Aminoglycoside antibiotic |
| pharmacokinetics | | absorption | Poorly absorbed orally, primarily administered as a stool preparation. | | distribution | Concentrates in the gastrointestinal tract, with limited systemic absorption. | | metabolism | Minimal hepatic metabolism, primarily eliminated renally, though not dependent on renal function for intestinal elimination. | | excretion | Primarily excreted via the feces. Some renal excretion. |
|
| suggested dosage | | adult | | oral | Administered as a stool preparation typically in a 1-3 g dose, up to 4-6 g depending on preparation and severity of infection | | intravenous | Generally not used in adults for oral preparations. |
| | notes | Dosage and duration depend on the specific indication. Consult a physician for appropriate dosage. |
|
| indications | | 1 | Treatment of intestinal amoebiasis and other intestinal infections | | 2 | Treatment of hepatic amoebic abscess | | 3 | Treatment of Traveler's diarrhea (occasionally) | | 4 | Treatment of certain types of bacterial intestinal infections |
|
| safety in pregnancy | | category | Category C | | details | Animal studies have shown adverse effects, but adequate studies in pregnant women are not available. Use only when potential benefits outweigh potential risks. |
|
| safety in breastfeeding | | category | Data limited | | details | Paromomycin is excreted into breast milk. Use with caution in nursing mothers. |
|
| side effects | | 1 | Nausea | | 2 | Vomiting | | 3 | Diarrhea | | 4 | Abdominal cramps | | 5 | Headache | | 6 | Dizziness | | 7 | Ototoxicity (hearing loss, balance problems) – potential, especially with higher doses or prolonged treatment; risk greater with co-administration of other ototoxic medications. | | 8 | Nephrotoxicity (kidney damage) – potential, especially with higher doses or prolonged treatment | | 9 | Allergic reactions |
|
| alternatives | |
| contraindications | | 1 | Known hypersensitivity to aminoglycoside antibiotics | | 2 | Severe renal impairment | | 3 | Known or suspected ototoxicity |
|
| interactions | | 1 | Aminoglycoside antibiotics (including other drugs in the same class) | | 2 | Other ototoxic drugs (e.g., loop diuretics, certain chemotherapy agents) | | 3 | Certain nephrotoxic drugs |
|
| warnings and precautions | | 1 | Monitor renal and auditory function during treatment, particularly with prolonged use or high doses | | 2 | Patients with pre-existing renal or auditory problems should be cautiously evaluated before treatment. | | 3 | Closely monitor for signs of ototoxicity or nephrotoxicity | | 4 | Avoid use during pregnancy unless critically needed and the potential benefits outweigh risks |
|
| additional informations | Paromomycin is not a first-line treatment for most infections. Appropriate use requires a proper clinical diagnosis. This information is for educational purposes only and does not constitute medical advice. Consult with a healthcare professional for diagnosis and treatment. |
| patient profile | |
